Skip to main content
Journal cover image

Post-Transplant Outcomes in High-Risk Compared with Non-High-Risk Multiple Myeloma: A CIBMTR Analysis.

Publication ,  Journal Article
Scott, EC; Hari, P; Sharma, M; Le-Rademacher, J; Huang, J; Vogl, D; Abidi, M; Beitinjaneh, A; Fung, H; Ganguly, S; Hildebrandt, G; Holmberg, L ...
Published in: Biol Blood Marrow Transplant
October 2016

Conventional cytogenetics and interphase fluorescence in situ hybridization (FISH) identify high-risk multiple myeloma (HRM) populations characterized by poor outcomes. We analyzed these differences among HRM versus non-HRM populations after upfront autologous hematopoietic cell transplantation (autoHCT). Between 2008 and 2012, 715 patients with multiple myeloma identified by FISH and/or cytogenetic data with upfront autoHCT were identified in the Center for International Blood and Marrow Transplant Research database. HRM was defined as del17p, t(4;14), t(14;16), hypodiploidy (<45 chromosomes excluding -Y) or chromosome 1 p and 1q abnormalities; all others were non-HRM. Among 125 HRM patients (17.5%), induction with bortezomib and immunomodulatory agents (imids) was higher compared with non-HRM (56% versus 43%, P < .001) with similar pretransplant complete response (CR) rates (14% versus 16%, P .1). At day 100 post-transplant, at least a very good partial response was 59% in HRM and 61% in non-HRM (P = .6). More HRM patients received post-transplant therapy with bortezomib and imids (26% versus 12%, P = .004). Three-year post-transplant progression-free (PFS) and overall survival (OS) rates in HRM versus non-HRM were 37% versus 49% (P < .001) and 72% versus 85% (P < .001), respectively. At 3 years, PFS for HRM patients with and without post-transplant therapy was 46% (95% confidence interval [CI], 33 to 59) versus 14% (95% CI, 4 to 29) and in non-HRM patients with and without post-transplant therapy 55% (95% CI, 49 to 62) versus 39% (95% CI, 32 to 47); rates of OS for HRM patients with and without post-transplant therapy were 81% (95% CI, 70 to 90) versus 48% (95% CI, 30 to 65) compared with 88% (95% CI, 84 to 92) and 79% (95% CI, 73 to 85) in non-HRM patients with and without post-transplant therapy, respectively. Among patients receiving post-transplant therapy, there was no difference in OS between HRM and non-HRM (P = .08). In addition to HRM, higher stage, less than a CR pretransplant, lack of post-transplant therapy, and African American race were associated with worse OS. In conclusion, we show HRM patients achieve similar day 100 post-transplant responses compared with non-HRM patients, but these responses are not sustained. Post-transplant therapy appeared to improve the poor outcomes of HRM.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Biol Blood Marrow Transplant

DOI

EISSN

1523-6536

Publication Date

October 2016

Volume

22

Issue

10

Start / End Page

1893 / 1899

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Transplantation, Autologous
  • Survival Analysis
  • Risk Assessment
  • Retrospective Studies
  • Multiple Myeloma
  • Middle Aged
  • Male
  • In Situ Hybridization, Fluorescence
  • Immunology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Scott, E. C., Hari, P., Sharma, M., Le-Rademacher, J., Huang, J., Vogl, D., … D’Souza, A. (2016). Post-Transplant Outcomes in High-Risk Compared with Non-High-Risk Multiple Myeloma: A CIBMTR Analysis. Biol Blood Marrow Transplant, 22(10), 1893–1899. https://doi.org/10.1016/j.bbmt.2016.07.007
Scott, Emma C., Parameswaran Hari, Manish Sharma, Jennifer Le-Rademacher, Jiaxing Huang, Dan Vogl, Muneer Abidi, et al. “Post-Transplant Outcomes in High-Risk Compared with Non-High-Risk Multiple Myeloma: A CIBMTR Analysis.Biol Blood Marrow Transplant 22, no. 10 (October 2016): 1893–99. https://doi.org/10.1016/j.bbmt.2016.07.007.
Scott EC, Hari P, Sharma M, Le-Rademacher J, Huang J, Vogl D, et al. Post-Transplant Outcomes in High-Risk Compared with Non-High-Risk Multiple Myeloma: A CIBMTR Analysis. Biol Blood Marrow Transplant. 2016 Oct;22(10):1893–9.
Scott, Emma C., et al. “Post-Transplant Outcomes in High-Risk Compared with Non-High-Risk Multiple Myeloma: A CIBMTR Analysis.Biol Blood Marrow Transplant, vol. 22, no. 10, Oct. 2016, pp. 1893–99. Pubmed, doi:10.1016/j.bbmt.2016.07.007.
Scott EC, Hari P, Sharma M, Le-Rademacher J, Huang J, Vogl D, Abidi M, Beitinjaneh A, Fung H, Ganguly S, Hildebrandt G, Holmberg L, Kalaycio M, Kumar S, Kyle R, Lazarus H, Lee C, Maziarz RT, Meehan K, Mikhael J, Nishihori T, Ramanathan M, Usmani S, Tay J, Vesole D, Wirk B, Yared J, Savani BN, Gasparetto C, Krishnan A, Mark T, Nieto Y, D’Souza A. Post-Transplant Outcomes in High-Risk Compared with Non-High-Risk Multiple Myeloma: A CIBMTR Analysis. Biol Blood Marrow Transplant. 2016 Oct;22(10):1893–1899.
Journal cover image

Published In

Biol Blood Marrow Transplant

DOI

EISSN

1523-6536

Publication Date

October 2016

Volume

22

Issue

10

Start / End Page

1893 / 1899

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Transplantation, Autologous
  • Survival Analysis
  • Risk Assessment
  • Retrospective Studies
  • Multiple Myeloma
  • Middle Aged
  • Male
  • In Situ Hybridization, Fluorescence
  • Immunology